The First Drug That Could Actually Treat This Childhood Disease Nobody Talks About
A rare childhood disease that robs kids of their ability to walk has never had an approved treatment. IntraBio's pivotal trial results and an FDA decision date in September could change that for the first time ever.
A Disease With No Answers
Imagine watching your child learn to walk, only to watch them slowly lose the ability. That's ataxia-telangiectasia.
A-T, as doctors call it, is a rare genetic disease that strikes in early childhood. It attacks the cerebellum, the part of the brain that controls coordination and balance. Kids who seem perfectly healthy at age two start stumbling by age five. Most are wheelchair-bound by their early teens. The disease also wrecks the immune system and dramatically raises cancer risk.
And until now, there has been zero approved treatments. Not one. Doctors could offer physical therapy, antibiotics for infections, and not much else. For a disease affecting roughly 1 in 40,000 to 100,000 children born worldwide, the medicine cabinet has been completely empty.
That just changed.
A Small Company With a Big Win
IntraBio, a rare disease biotech with roots at Oxford and Munich, just dropped pivotal Phase III results for its drug levacetylleucine (brand name AQNEURSA) in A-T. The trial hit its primary endpoint with flying colors.
The study, called IB1001-303, enrolled pediatric and adult A-T patients across multiple countries. It used a crossover design: patients got either the drug or placebo for 12 weeks, then switched. The main measure was something called the SARA score, a 40-point scale that grades how well someone can walk, stand, sit, speak, and coordinate their limbs. Lower is better.
Patients on levacetylleucine improved their SARA score by 1.92 points. Patients on placebo? Basically flat, at 0.14 points. The treatment difference of 1.88 points hit p < 0.001, which in statistics-speak means this almost certainly wasn't a fluke.
For context, in a progressive disease where patients normally get worse over time, any improvement is notable. Nearly two points of improvement in just 12 weeks is the kind of result that makes neurologists sit up straight.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
A single positive endpoint is good. Multiple positive endpoints tell a much more convincing story.
The trial also measured the ICARS scale, another ataxia rating tool that evaluates posture, gait, limb movement, and speech. Levacetylleucine beat placebo here too, with a 4.22-point improvement versus 1.69 for placebo (p = 0.003).
Doctors running the trial were also asked to rate each patient's overall clinical improvement on a standardized scale. Once again, patients on the drug did significantly better (p = 0.02). When the investigators themselves can tell who's getting the real drug in a blinded study, that's a powerful signal.
Perhaps most impressive: the safety data. Levacetylleucine actually had fewer adverse events than placebo (54 versus 75). There were no drug-related serious side effects. No deaths. No single side effect showed up in more than 10% of treated patients. In a vulnerable population of kids and adults with compromised immune systems, that kind of safety profile is almost too clean.
Not IntraBio's First Rodeo
This isn't the company's debut at the regulatory dance. IntraBio already secured FDA approval for AQNEURSA in Niemann-Pick disease type C (NPC), another devastating rare neurological condition. That approval came in 2024, based on a similarly designed Phase III trial that showed significant improvement in cerebellar ataxia symptoms.
The NPC playbook is essentially being repeated here: same drug, same type of crossover trial, same primary endpoint (SARA), same favorable safety profile.
Think of it like a chef who nailed a recipe at one restaurant and is now opening a second location. The ingredients are proven; the question is whether regulators agree the dish works in a new setting.
The Regulatory Clock Is Ticking
It turns out the FDA is already intrigued. IntraBio filed a supplemental New Drug Application (basically asking to add A-T to AQNEURSA's existing label), and the FDA didn't just accept it. The agency granted Priority Review, which is reserved for drugs that could offer significant improvements over available therapy.
Since there is no available therapy for A-T, that bar is about as low as it gets.
The target decision date: September 19, 2026. That's barely two months away. For investors and, more importantly, for families dealing with A-T, this is the date circled on the calendar in red ink.
IntraBio has also signaled plans to file in Europe (with the EMA) and other global markets, though specific timelines for those submissions haven't been disclosed yet.
What Could Go Wrong?
Let's be honest about the risks, because no biotech story is complete without them.
First, the 12-week treatment period is relatively short. Regulators will want to see long-term data from the ongoing extension study to confirm that benefits last and no late-appearing safety issues emerge. The NPC extension data helps here, but A-T is a different disease with different progression dynamics.
Second, the crossover design can sometimes raise questions about carryover effects: did the drug's impact linger into the placebo period, potentially muddying the results? This is a known consideration, though IntraBio presumably built statistical safeguards into the trial design.
Third, and this is important to keep in perspective: levacetylleucine does not fix the underlying genetic defect in A-T. The ATM gene mutation that causes the disease remains. This drug stabilizes cerebellar neurons and improves motor function, which is genuinely meaningful for quality of life. But it's a symptomatic treatment, not a cure. The immune problems, cancer risk, and other systemic features of A-T persist.
Why This Matters Beyond the Numbers
Rare disease drug development is brutally hard. Patient populations are tiny. Recruitment takes years. Endpoints are debated endlessly. Many companies simply avoid the space because the economics don't pencil out without orphan drug incentives.
IntraBio, funded through a mix of venture rounds (including a $15 million Series C in 2023 and a $40.3 million raise in 2024), has methodically built a platform around a single molecule and expanded it across multiple rare neurological diseases. That strategy is now producing real clinical wins.
For the roughly one in every 40,000 to 100,000 children born with A-T, a positive FDA decision in September would mean something unprecedented: the first time a doctor could write a prescription specifically for their disease. Not a workaround. Not an off-label hope. An actual approved treatment.
After decades of empty-handed doctor visits, that's not just a regulatory milestone. It's a lifeline.
Funding & Financings
5 min read
The Gene Editing Company That Wants to Replace Your Cholesterol Meds
A gene editing startup co-founded by a Nobel laureate just filed to go public, and it's not chasing rare diseases. Scribe Therapeutics wants to use CRISPR to replace your daily cholesterol pills with a single dose that silences the genes behind heart disease.
